Form 144: Restricted stock sale notice — Kala Pharmaceuticals (NASDAQ: KALA)
Rhea-AI Filing Summary
Morgan Stanley Smith Barney LLC submitted a Form 144 reporting proposed sales of restricted Common Stock of KALA. The notice lists multiple restricted-stock lots with specific lot sizes and grant/vesting dates, including 01/30/2026 (2,450 shares) and 06/11/2025 (1,400 shares).
The filing lists additional restricted-stock lots (e.g., 397; 1,261; 800; 222; 221; 1,100 shares) tied to grant or restriction dates shown in the table. The filing is a broker notice of proposed sales under Rule 144; timing and aggregate proceeds are not stated in the provided excerpt.
Positive
- None.
Negative
- None.
Insights
Rule 144 notice for proposed resale of restricted shares; procedural compliance is the core action.
The filing lists multiple restricted Common Stock lots for KALA with grant/restriction dates such as 06/11/2025 and 01/30/2026 and per‑lot share counts (for example, 2,450 and 1,400 shares). The form functions as a broker notice under resale rules.
Final sale timing, aggregate amount, and purchaser details are not included in the excerpt; subsequent filings or broker confirmations would show execution and proceeds. Continued compliance with holding‑period and public‑information conditions under Rule 144 will determine whether the sales are permitted.
Administrative resale filing; market impact depends on actual sales, not the notice itself.
The entry lists multiple restricted‑stock lots by date and share count (examples: 01/30/2026 — 2,450 shares; 06/11/2025 — 1,400 shares). The form notifies the broker and regulator of intent to sell under Rule 144 constraints.
Because the form does not state aggregate proceeds or execution method, the economic effect hinges on whether and when the broker executes sales and whether selling holders satisfy holding‑period and public information conditions.